Juliane Mietz
Zurich, ZH, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells.
Journal: Molecular therapy. Oncology
Published: January 31, 2025
EBV induces CNS homing of B cells attracting inflammatory T cells.
Journal: Nature
Published: September 20, 2024
Stem cell memory EBV-specific T cells control EBV tumor growth and persist in vivo.
Journal: Science advances
Published: August 23, 2024
CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison.
Journal: Experimental hematology & oncology
Published: October 29, 2023
Human effector CD8+ T cells with an activated and exhausted-like phenotype control tumour growth in vivo in a humanized tumour model.
Journal: EBioMedicine
Published: October 01, 2023
The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells.
Journal: Scientific reports
Published: April 20, 2023
Targeted adenovirus-mediated transduction of human T cells in vitro and in vivo.
Journal: Molecular therapy. Methods & clinical development
Published: November 21, 2022
Neuraminidase Inhibitor Zanamivir Ameliorates Collagen-Induced Arthritis.
Journal: International journal of molecular sciences
Published: December 27, 2020
Reduced frequency of cytotoxic CD56dim CD16+ NK cells leads to impaired antibody-dependent degranulation in EBV-positive classical Hodgkin lymphoma.
Journal: Cancer immunology, immunotherapy : CII
Published: April 11, 2020
Showing 1-10 of 10
Last Updated: 09/26/2026